

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
22 September 2022 (22.09.2022)



(10) International Publication Number
WO 2022/198062 A2

(51) International Patent Classification:

C07D 265/30 (2006.01) A61K 31/5377 (2006.01)
C07D 413/12 (2006.01) A61P 25/00 (2006.01)
A61K 31/5375 (2006.01)

(21) International Application Number:

PCT/US2022/020976

(22) International Filing Date:

18 March 2022 (18.03.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/162,671 18 March 2021 (18.03.2021) US

(71) Applicant: SUPERNUS PHARMACEUTICALS, INC.

[US/US]; 9715 Key West Ave., Rockville, Maryland 20850 (US).

(72) Inventor: PADIA, Janak Khimchand; c/o Supernus Pharmaceuticals, INC., 9715 Key West Ave., Rockville, Maryland 20850 (US).

(74) Agent: MAEBIUS, Stephen et al.; Foley & Lardner LLP, 3000 K Street NW, Suite 600, Washington, District of Columbia 20007-5109 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available):

AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available):

ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- without international search report and to be republished upon receipt of that report (Rule 48.2(g))

(54) Title: DERIVATIVES OF SUBSTITUTED MORPHOLINES AND USES THEREOF



(57) Abstract: A compound of Formula I includes a stereoisomer thereof and/or a salt thereof; wherein R¹ is a substituted alkane group, a heterocyclic group, or a pyridine group; X is hydrogen, a halogen, an amino acid residue, a substituted amino acid residue, an alkyl group, or an ester. Such compounds may be used in pharmaceutical compositions and for the treatment of central nervous system (CNS) disorders:

WO 2022/198062 A2